Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Разработка технологии вирусоподобных частиц от небольших высоко симметричных до крупных сложных структур вирусоподобных частиц
2013-01-01
SCID: 54.1/8ujt9s2a
Discuss with AI
HPV vaccination recommendations (ACIP)HPV-associated diseases and burdenhuman papillomavirus vaccine (HPV4)quadrivalent HPV vaccinevirus-like particle technology
Figures from the paper
Abstract (AI)
On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers and genital warts). The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of females at age 11 or 12 years and catch-up vaccination for females aged 13 through 26 years. On October 21, 2009, ACIP provided guidance that HPV4 may be given to males aged 9 through 26 years to reduce their likelihood of acquiring genital warts; ACIP does not recommend HPV4 for routine use among males. This report presents the ACIP policy statement and summarizes background data. Issues reviewed by ACIP included efficacy, immunogenicity, and safety of the HPV4 vaccine in males, epidemiology of HPV and burden of HPV-associated diseases and cancers in males, cost-effectiveness of male vaccination, and programmatic considerations.
Key Findings
1
ACIP recommends routine HPV vaccination for females at age 11–12 with catch-up vaccination for females aged 13–26.
2
ACIP reviewed male-specific data on vaccine efficacy, immunogenicity, safety, HPV epidemiology and disease burden in males, cost-effectiveness, and programmatic considerations when forming the policy.
3
HPV4 was previously licensed for females aged 9–26 to prevent HPV 6, 11, 16, and 18-related outcomes including vaginal, vulvar, and cervical precancers, cancers, and genital warts.
4
On October 16, 2009 the FDA licensed the quadrivalent HPV vaccine (HPV4; Gardasil) for males aged 9–26 to prevent genital warts caused by HPV types 6 and 11.
5
On October 21, 2009 ACIP advised that HPV4 may be given to males aged 9–26 to reduce genital wart acquisition but did not recommend routine use among males.
Research Object
Virus-like particles (VLP) technology and virus-like particle structures
Research Subject
Development and scaling of VLP technology from small highly symmetric to large complex VLP structures, including implications for vaccine design and immunogenicity
Publication Details
Publication Date
2013-01-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest